Growing demand for intravenous vaccine delivery mode is augmenting growth of the Hypodermic Needles Market

 


A hypodermic needle is a small and solid needle with an outer ring that fits inside the body like a pen. A hypodermic needle is designed to deliver a very small amount of liquid directly to a localized part of the body. This type of needle may be used for administering many different types of medication, including pain killers, chemotherapy drugs, and vaccines. Also, a hypodermic needle is used in many surgical procedures, such as those that remove portions of the lung or colon. The most commonly used hypodermic needles are those that are manufactured and sold under the name "syringe" or "infusion needle."

Growing demand for intravenous vaccine delivery mode is primarily driving the growth of the Hypodermic Needles Market. Moreover, the growing prevalence of chronic diseases and rising compliance for safety needles in order to reduce the cases of needlestick injuries is again fostering the growth of the hypodermic needle market. According to the National Health Council, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country. By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.

North America is expected to hold the dominant position in the global Hypodermic Needles Market and this can be accredited to the increasing adoption of strategic partnership by key players in the region. For instance, in July 2020, Smiths Medical, a global medical device manufacturer, announced a strategic public-private partnership with Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). The goal of the partnership is to increase the production of integrated hypodermic needle and syringe products to support the government’s COVID-19 vaccination efforts.

Key Developments:

  1. In April 2021, Nipro PharmaPackaging Launches CURACASE™ – Hypodermic Needles in Hard-Plastic Unit Packaging. The launch of the CURACASE™ needles further strengthens our ability to manufacture and supply complete injection systems for the pharmaceutical industry.

  2. In December 2018, Terumo Corporation announced that a biosimilar, which uses the company’s PLAJEX™ pre-fillable syringe, has launched in Europe. Terumo manufactures the product Hulio®, a biosimilar to Humira® (adalimumab), on contract. This marks an important milestone, as the first overseas commercial launch for PLAJEX™

  3. In April 2021, West Pharmaceutical Services (West), provider of injectable drug administration, has announced its partnership with domestic Indian pharma company Venus Remedies for prefilled ISO standard 1mL long staked needle syringes.



See Full Report@ https://www.coherentmarketinsights.com/ongoing-insight/hypodermic-needles-market-1102


Comments

Popular posts from this blog

Cross Linked Polyethylene Market Growth Accelerated by Increasing demand from pipe and cables application

Soda Ash Is An Essential Component Of Water Treatment

It Is Incredibly Effective To Create A Cohesive Online And In-Store Experience Using Smart Beacons